Vitamin Market Outlook
Q3 conditions are expected to include firm pricing, selective supply constraints, and extended lead times, supported in part by several planned summer maintenance shutdowns among key producers. While not all vitamins are equally tight, the broader market environment suggests limited immediate downward pressure.
Across key vitamins, supply constraints and cost pressures continue to shape market conditions.
Vitamin E remains one of the tighter segments, with availability affected by maintenance in China, reduced European output—further impacted by a production outage at a key regional producer and upcoming 4–6 week summer shutdowns—and delayed capacity expansions. Inventories are reported to be below typical levels in some regions, and current price levels are generally seen as well supported.
Vitamin A reflects similar dynamics, with supply influenced by maintenance cycles, variability in exports from China, and the lingering impact of an earlier production outage at a key European producer. Pricing remains elevated, with a continued firm tone.
In B vitamins, rising input costs are playing an increasingly important role. Vitamin B1 is expected to keep firm due to supply constraints and higher production costs, while Vitamin B3 (Niacin) continues to reflect tight availability, cost pressure, and relatively uncovered demand entering the quarter.
Vitamin B2 has stabilized following earlier increases but is expected to keep firm, particularly in Europe where supply constraints persist. Vitamin B9 (Folic Acid) has moved into a higher pricing range, with prices continuing to increase, supported by supply constraints, raw material tightness, and steady procurement activity.
Vitamin B12 expected to keep firm overall, with regional variation. European prices continue to reflect limited approved supply sources, while other regions show modest firming linked to input costs. U.S. pricing remains comparatively higher, influenced in part by tariff structures.
Other vitamin segments appear more balanced, though still influenced by broader cost dynamics.
Vitamin D3 reflects a relatively balanced market, where supply appears sufficient to meet demand despite ongoing constraints. Prices have slightly softened. Increased competitive activity and new approved sources may gradually influence regional pricing alignment, while delayed capacity expansions limit major supply shifts.
Vitamin C highlights the impact of cost inflation. Despite structural oversupply, rising raw material costs and limited producer offers are supporting firmer pricing. This is further reinforced by sustained demand levels, with some volumes still uncovered, contributing to continued upward pressure and keeping the market firm.
Vitamin B5 has shifted toward a more producer-led environment. Constrained availability and cautious quoting behavior have been supporting upward pricing momentum. The sustainability of this trend remains uncertain.
Vitamin B6 remains relatively stable, with structural oversupply helping offset broader cost pressures. However, competitive activity—particularly from Chinese suppliers—continues to influence pricing dynamics and the timing of potential new market entries.
Vitamin B7 reflects a well-supplied market. Production has normalized, and many buyers remain covered under longer-term contracts, limiting near-term price movement. Soft demand and additional capacity may continue to weigh on the outlook.
Vitamin K3 prices are expected to keep firm in view of the continued availability constraints, uncertainty in the producer outlook and rising cost.
Conclusion
The Q3 2026 vitamin market reflects a structurally tight and cost-sensitive environment, with macroeconomic pressures, supply constraints, and evolving procurement strategies continuing to support a firm overall tone. While conditions vary across segments, ongoing maintenance activity, constrained output, and persistent cost inflation are limiting downside risk.
At the same time, the market remains uneven and reactive, shaped by mixed demand patterns and differing procurement approaches. With limited visibility and continued exposure to geopolitical and supply-side disruptions, maintaining flexibility, close market monitoring, and disciplined decision-making will be key in navigating the months ahead.
